- Home
- IMMP vs SSBK Comparison
IMMP vs SSBK Comparison
Compare IMMP & SSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- SSBK
- Stock Information
- Founded
- IMMP 1987
- SSBK 2007
- Country
- IMMP Australia
- SSBK United States
- Employees
- IMMP N/A
- SSBK N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- SSBK Commercial Banks
- Sector
- IMMP Health Care
- SSBK Finance
- Exchange
- IMMP Nasdaq
- SSBK Nasdaq
- Market Cap
- IMMP 211.1M
- SSBK N/A
- IPO Year
- IMMP N/A
- SSBK 2021
- Fundamental
- Price
- IMMP $1.86
- SSBK $35.53
- Analyst Decision
- IMMP Buy
- SSBK Buy
- Analyst Count
- IMMP 2
- SSBK 1
- Target Price
- IMMP $8.50
- SSBK $36.00
- AVG Volume (30 Days)
- IMMP 648.0K
- SSBK 41.8K
- Earning Date
- IMMP 05-16-2025
- SSBK 04-21-2025
- Dividend Yield
- IMMP N/A
- SSBK 1.01%
- EPS Growth
- IMMP N/A
- SSBK 6.02
- EPS
- IMMP N/A
- SSBK 3.80
- Revenue
- IMMP $3,019,249.00
- SSBK $99,026,000.00
- Revenue This Year
- IMMP $11.25
- SSBK $19.18
- Revenue Next Year
- IMMP $10.22
- SSBK $7.05
- P/E Ratio
- IMMP N/A
- SSBK $9.36
- Revenue Growth
- IMMP 24.11
- SSBK 18.43
- 52 Week Low
- IMMP $1.32
- SSBK $24.86
- 52 Week High
- IMMP $3.34
- SSBK $39.16
- Technical
- Relative Strength Index (RSI)
- IMMP 53.43
- SSBK 63.53
- Support Level
- IMMP $1.44
- SSBK $34.44
- Resistance Level
- IMMP $2.71
- SSBK $35.37
- Average True Range (ATR)
- IMMP 0.17
- SSBK 0.74
- MACD
- IMMP 0.05
- SSBK 0.28
- Stochastic Oscillator
- IMMP 29.75
- SSBK 93.37
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.